

Daclatasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)	<p>Chronic hepatitis C</p> <p>Therapeutic equivalent to glecaprevir + pibrentasvir for</p> <p>Chronic hepatitis C</p> <p>Therapeutic equivalent to sofosbuvir + velpatasvir for</p> <p>Chronic hepatitis C</p> <p>Therapeutic equivalent to sofosbuvir for</p> <p>Chronic hepatitis C</p>

Dasabuvir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 250 mg tablet	<p>Chronic hepatitis C</p>

Elbasvir + grazoprevir

Section	Indications
Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations Oral > Solid: 50 mg + 100 mg	<p>Chronic hepatitis C</p>

Glecaprevir + pibrentasvir

Section	Indications
Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations Oral > Solid: 100 mg + 40 mg tablet	<p>Therapeutic equivalent to daclatasvir for</p> <p>Chronic hepatitis C</p> <p>Chronic hepatitis C</p> <p>Therapeutic equivalent to sofosbuvir + velpatasvir for</p> <p>Chronic hepatitis C</p> <p>Therapeutic equivalent to sofosbuvir for</p> <p>Chronic hepatitis C</p>

Ledipasvir + sofosbuvir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
Oral > Solid: 90 mg + 400 mg tablet

Indications

Chronic hepatitis C

Ombitasvir + paritaprevir + ritonavir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet

Indications

Chronic hepatitis C

Pegylated interferon alfa (2a)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C
Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe

Indications

Chronic hepatitis C

Pegylated interferon alfa (2b)

Section

Medicines for hepatitis C > Other antivirals for hepatitis C
Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe

Indications

Chronic hepatitis C

Ribavirin

Section

Medicines for hepatitis C > Other antivirals for hepatitis C
Parenteral > General injections > IV: 1000 mg per 10 mL phosphate buffer solution; 800 mg per 10 mL phosphate buffer solution
Oral > Solid: 200 mg; 400 mg; 600 mg

Indications

Chronic hepatitis C

Simeprevir

Section

Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
Oral > Solid: 150 mg

Indications

Chronic hepatitis C

Sofosbuvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 400 mg tablet

Indications

Therapeutic equivalent to **daclatasvir** for

Chronic hepatitis C

Therapeutic equivalent to **glecaprevir + pibrentasvir** for

Chronic hepatitis C

Therapeutic equivalent to **sofosbuvir + velpatasvir** for

Chronic hepatitis C

Chronic hepatitis C

Sofosbuvir + velpatasvir

Section

Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

Oral > Solid: 400 mg + 100 mg tablet

Indications

Therapeutic equivalent to **daclatasvir** for

Chronic hepatitis C

Therapeutic equivalent to **glecaprevir + pibrentasvir** for

Chronic hepatitis C

Chronic hepatitis C

Therapeutic equivalent to **sofosbuvir** for

Chronic hepatitis C